Brody, Joshua
https://orcid.org/0000-0002-0850-6730
Mayo Clinic
Icahn School of Medicine at Mount Sinai
Citations 11
A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).
Armand, Philippe , Shustov, Andrei R., Moskowitz, Alison J. , Josephson, Neil C. , Salles, Gilles , Masood, Aisha, Ansell, Stephen M. , Salles, Gilles A , Brody, Joshua , Barr, Paul M. , Kline, Justin Paul , Savage, Kerry J. , Kuruvilla, John , Zinzani, Pier Luigi
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7576-TPS7576
